Evoke Pharma

Yahoo Finance • last month

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma,... Full story

Yahoo Finance • 2 months ago

Wondering what's happening in today's pre-market session?

Wondering what's happening in Friday's pre-market session? Find an overview in this article. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT EEIQ [https://www.chartmill.com/stock/quote/EEIQ/profile] 127.0% EPICQUEST... Full story

Yahoo Finance • 2 months ago

Thursday's after hours session: top gainers and losers

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] GAINERS TICKER CHANGE COMMENT MODV [https://www.chartmill.com/stock/quote/MODV/... Full story

Yahoo Finance • 2 months ago

These stocks that are showing activity before the opening bell on Thursday.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT AP... Full story

Yahoo Finance • 2 months ago

Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide)... Full story

Yahoo Finance • 2 months ago

Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

SOLANA BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal sp... Full story

Yahoo Finance • 2 months ago

Evoke reaffirms FY25 guidance, implies 3% profit beat on stronger margins

Investing.com -- Evoke (LON:EVOK) on Wednesday reaffirmed its fiscal 2025 revenue growth forecast of 5% to 9% and projected EBITDA margins of at least 20%, which at the lower end of guidance equates to about £368 million, roughly 3% above... Full story

Yahoo Finance • 2 months ago

evoke reports 3% revenue growth and 44% adjusted EBITDA increase in H1 2025

LONDON - evoke Plc (LSE:EVOK), one of the world’s leading betting and gaming companies, reported a 3% increase in revenue to £887.8 million and a 44% jump in Adjusted EBITDA to £165.9 million for the first half of 2025, marking its fourth... Full story

Yahoo Finance • 2 months ago

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

SOLANA BEACH, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide)... Full story

Yahoo Finance • 3 months ago

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.49%

Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Technology, Utilities and Industrials sectors led shares higher. At the close in NYSE, the Dow Jones Industrial Average gained 0.49%, while the S&P 500... Full story

Yahoo Finance • 3 months ago

Evoke Pharma stock soars after receiving patent allowance for GIMOTI

Investing.com -- Evoke Pharma Inc (NASDAQ:EVOK) stock surged 50% after the specialty pharmaceutical company received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering its gastropares... Full story

Yahoo Finance • 3 months ago

Evoke Pharma receives patent allowance for gastroparesis nasal spray

SOLANA BEACH, Calif. - Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company with a market capitalization of $5.38 million and impressive revenue growth of ~90% over the last twelve months, has received a Notice of Allowance... Full story

Yahoo Finance • 3 months ago

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide)... Full story

Yahoo Finance • 3 months ago

evoke director Andrea Gisle Joosen to join Atlantic Grupa board

LONDON - Evoke plc announced Thursday that Andrea Gisle Joosen, Independent Non-Executive Director at the company, will be appointed as a member of the Supervisory Board of Atlantic Grupa d.d., effective September 4, 2025. The appointment... Full story

Yahoo Finance • 4 months ago

Andrea Gisle Joosen appointed to Grafton Group board

LONDON - Evoke PLC announced Wednesday that Andrea Gisle Joosen, an Independent Non-Executive Director at the company, has been appointed as Non-Executive Director of Grafton Group plc, effective July 1, 2025. According to the company sta... Full story

Yahoo Finance • 5 months ago

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: E... Full story

Yahoo Finance • 7 months ago

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in... Full story

Yahoo Finance • 7 months ago

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal sp... Full story

Yahoo Finance • 7 months ago

Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide)... Full story

Yahoo Finance • 2 years ago

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide)... Full story